Učitavanje...
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
INTRODUCTION: Targeted therapy for NSCLC is rapidly evolving. EGFR-TKIs benefit NSCLC patients with sensitive EGFR mutations and significantly prolong survival. However, 20–30% of patients demonstrate primary resistance to EGFR-TKIs, which leads to the failure of EGFR-TKI treatment. The mechanisms o...
Spremljeno u:
| Izdano u: | Mol Med |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7329552/ https://ncbi.nlm.nih.gov/pubmed/32611363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10020-020-00193-z |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|